Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 226

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

Besse, Benjamin, Le Moulec, Sylvestre, Mazières, Julien, Senellart, Hélène, Barlesi, Fabrice, Chouaid, Christos, Dansin, Eric, Bérard, Henri, Falchero, Lionel, Gervais, Radj, Robinet, Gilles, Ruppert, Anne-Marie, Schott, Roland, Léna, Hervé, Clément-Duchêne, Christelle, Quantin, Xavier, Souquet, Pierre Jean, Trédaniel, Jean, Moro-Sibilot, Denis, Pérol, Maurice, Madroszyk, Anne-Catherine, Soria, Jean-Charles · 2015 · Clinical Cancer Research

Abstract

Purpose: The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non–small cell lung cancer (NSCLC) and asymptomatic untreated brain metastases to provide data in this previously unexplored subgroup. Experimental Design: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0–1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve ×6) and paclitaxel (200 mg/m2) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). Six-month progression-free survival (PFS) was the primary endpoint. The trial could be stopped if there were more than three (B + CP) or more than two (B + E) intracranial hemorrhages. Results: In first-line B + CP cohort (n = 67), 6-month PFS rate was 56.5% with a median PFS of 6.7 months [95% confidence interval (CI), 5.7–7.1] and median overall survival (OS) of 16.0 months. Investigator-assessed overall response rate (ORR) was 62.7%: 61.2% in intracranial lesions and 64.2% in extracranial lesions. Because of low enrolment (n = 24), efficacy results for the second-line B + E cohort were exploratory only; 6-month PFS rate was 57.2%, median PFS was 6.3 months (95% CI, 3.0–8.4), median OS was 12.0 months, and ORR was 12.5%. Adverse events were comparable with previous trials of bevacizumab. One grade 1 intracranial hemorrhage occurred and resolved without sequelae. Conclusions: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. Clin Cancer Res; 21(8); 1896–903. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2082

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 226

Metadata

Authors
Besse, B., Le Moulec, S., Mazières, J., Senellart, H., Barlesi, F., Chouaid, C., Dansin, E., Bérard, H., Falchero, L., Gervais, R., Robinet, G., Ruppert, A.-M., Schott, R., Léna, H., Clément-Duchêne, C., Quantin, X., Souquet, P. J., Trédaniel, J., Moro-Sibilot, D., Pérol, M., Madroszyk, A.-C., & Soria, J.-C.
Venue
Clinical Cancer Research
Published
2015-04-14
Volume
21
Issue
8
Pages
1896-1903
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2136371443
Cited by
226
References
2
FWCI
20.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2082
The paper
Besse, B., Le Moulec, S., Mazières, J., Senellart, H., Barlesi, F., Chouaid, C., Dansin, E., Bérard, H., Falchero, L., Gervais, R., Robinet, G., Ruppert, A.-M., Schott, R., Léna, H., Clément-Duchêne, C., Quantin, X., Souquet, P. J., Trédaniel, J., Moro-Sibilot, D., . . . Soria, J.-C. (2015). Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.